Home ›
Hepatocellular Carcinoma (HCC) Liver Cancer Trials ›
NCT06609876
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
Trial Details
NCT ID NCT06609876
Phase NA
Sponsor Sun Yat-sen University
Status RECRUITING
Cancer Type Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions Thermal ablation Donafenib
Locations (sample) Beijing, None Selected, China|39.9075,116.39723
Key Eligibility Criteria
were aged 18-75 years; had recurrent HCC (RHCC) diagnosed by imaging studies, the first or the second RHCC; RHCC met the Milan criteria, namely single RHCC lesion less than 5 cm in diameter or no more than 3 tumors (each ≤3 cm in diameter); the early RHCC (recurrent time \<1 year)
For full eligibility, visit ClinicalTrials.gov .